Nan Fung Trinity HK Ltd. Invests $11.72 Million in Danaher Corporation $DHR

Nan Fung Trinity HK Ltd. acquired a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 59,100 shares of the conglomerate’s stock, valued at approximately $11,717,000.

Other hedge funds have also recently bought and sold shares of the company. WFA of San Diego LLC bought a new position in Danaher during the 2nd quarter worth about $26,000. Howard Hughes Medical Institute bought a new position in shares of Danaher during the second quarter worth about $27,000. TruNorth Capital Management LLC acquired a new stake in Danaher in the 3rd quarter valued at approximately $28,000. Tripletail Wealth Management LLC bought a new stake in Danaher in the 3rd quarter valued at approximately $31,000. Finally, Red Tortoise LLC boosted its position in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after acquiring an additional 98 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Analyst Ratings Changes

A number of brokerages have recently commented on DHR. TD Cowen reissued a “buy” rating on shares of Danaher in a research report on Wednesday, January 7th. Guggenheim raised their price objective on Danaher from $250.00 to $275.00 and gave the company a “buy” rating in a report on Friday, January 2nd. JPMorgan Chase & Co. upped their target price on Danaher from $270.00 to $275.00 and gave the stock an “overweight” rating in a report on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of Danaher in a research note on Monday, December 29th. Finally, Robert W. Baird set a $251.00 price objective on Danaher in a research note on Thursday. Twenty analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $252.32.

Danaher Stock Down 0.4%

NYSE DHR opened at $218.82 on Friday. The company has a current ratio of 1.87, a quick ratio of 1.10 and a debt-to-equity ratio of 0.35. The company has a market cap of $154.56 billion, a price-to-earnings ratio of 43.42, a PEG ratio of 3.12 and a beta of 0.89. The company has a 50 day moving average of $230.60 and a 200-day moving average of $213.96. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.79 billion. During the same period in the prior year, the company earned $2.14 EPS. Danaher’s revenue for the quarter was up 4.6% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, December 26th. Danaher’s payout ratio is presently 25.40%.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This trade represents a 59.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is currently owned by company insiders.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.